secwatch.observer — SEC 8-K summary
======================================

Issuer:     REATA PHARMACEUTICALS INC (—)
CIK:        0001358762
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0000950170-23-005600
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reata Pharmaceuticals amends bylaws to update director nomination procedures and exclusive forum provisions
--------------------------------------------------------------------------------

- Board of Directors approved Third Amended and Restated Bylaws effective March 1, 2023.
- Amendments revise procedures and disclosure requirements for director nominations to comply with SEC Rule 14a-19.
- Bylaws designate federal district courts as exclusive forum for Securities Act of 1933 claims.
- Updates made to indemnification provisions and other administrative changes to conform with Delaware General Corporation Law.
- Exhibit 3.1 filed with the 8-K contains the full text of the Amended and Restated Bylaws.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1358762/000095017023005600/0000950170-23-005600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1358762/000095017023005600/reta-20230301.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer